Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazlestobart - ImmuneOnco Biopharma

Next Previous
Drug Profile

Tazlestobart - ImmuneOnco Biopharma

Alternative Names: AXN-27M; IMM-27M; SYN-27M

Latest Information Update: 08 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Class Antineoplastics; Gene therapies; Immunoglobulins; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 27 Aug 2026 Phase-II clinical trials in Liver cancer (Combination therapy, Late-stage disease, First-line therapy) (Parenteral) prior to August 2026
  • 27 Aug 2026 Efficacy and adverse events data from a phase I trial in Solid tumours released by ImmuneOnco Biopharma
  • 07 Jul 2026 ImmuneOnco Biopharmaceuticals plans a phase II trial in Liver cancer (Late-stage disease, First-line therapy, Combination therapy) in July 2026 (IV) (NCT07687914)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top